{
    "doi": "https://doi.org/10.1182/blood-2021-148263",
    "article_title": "Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials ",
    "article_date": "November 5, 2021",
    "session_type": "618.Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis",
    "abstract_text": "Background: Genetic information has become critical to understand the development of T-cell acute lymphoblastic leukemia (T-ALL) and to elucidate the origin of disease relapse. Several genetic markers, together with measurable residual disease (MRD), are considered strong predictors of patient outcome. However, the prognostic significance of genetic markers can varie according to treatment. Aim: We used targeted deep sequencing to analyze the genetic profile of 125 T-ALL patients enrolled in three consecutive MRD-oriented trials from the Spanish PETHEMA (Programa Espa\u00f1ol de Tratamientos en Hematolog\u00eda) group. Genomic information was analyzed together with the main clinical and biologic data in a subset of 111 patients with detailed clinical and outcome data to determine the prognostic significance for overall survival (OS) and cumulative incidence of relapse (CIR). Methods: Genetic mutations were detected using a custom gene panel and sequenced on a MiSeq platform. Alignment, variant calling, filtration and annotation of variants were done using standardized pipelines. OS curves were plotted by the Kaplan-Meier method and compared by the log-rank test. CIR was estimated using cumulative incidence functions by competing risks analysis. A Cox proportional hazard regression model was used to identify predictive factors for OS. Statistical significance was set at (two-sided) p-values <0.05. Results: Recurrently mutated genes found in \u22654/125 patients involved transcription factor tumor suppressor genes ( PTEN, BCL11B, RUNX1, GATA3, ETV6 ), epigenetic regulators ( PHF6, DNMT3A, EP300, KMT2C, EZH2, TET2 ), DNA mismatch repair genes ( MSH2 ), ribosomal ( RPL5 ) and RNA splicing ( U2AF1 ) genes, and genes involved in the RAS/MAPK ( NRAS ), WNT ( FAT1, FAT3 ), IL7R-JAK-STAT ( JAK3, JAK1, IL7R ) and NOTCH1 signaling pathways, respectively. Mutations in the latest pathway (NOTCH1 & FBXW7) was found in 88/125 (70%) patients. Clinical-genetic correlations revealed that patients with mutations in JAK3, DNMT3A, N/KRAS, IL7R, MSH2 or in U2AF1 were associated with lower OS ( vs unmutated patients). None of the mutated genes had impact on CIR. Upon grouping the mutated genes according to their functional role and potential biological impact on T-ALL, two gene signatures were defined. These included the aging gene signature ( DNMT3A and U2AF1 ) characterized by mutations in genes identified in clonal hematopoiesis of indeterminate potential (CHIP); and the treatment resistance gene signature ( JAK3 , N/KRAS , IL7R and MSH2 ), defined by mutations in genes involved in resistance to the ALL therapy. Both clusters identified patients with poorer response to therapy (poorer blast clearance on day 14 of induction treatment and lower CR rates). Therefore, we considered together (worse outcome genetics [WOG] signature) for univariate and multivariate analyses. WOG and MRD level (0.1% cut-off) on day 35 after induction therapy (+35d MRD) showed significant prognostic impact in the univariable and multivariable analyses for OS (3y) with a hazard ratio (95% CI) of 2.4 (1.2; 4.8) and 2.7 (1.4; 5.1), respectively (Table 1). OS according to these two variables allowed risk stratification of T-ALL into low, intermediate- and high-risk (HR) patients with significantly different outcomes (p<0.001) (Figure 1). Conclusion: A genetic signature with independent prognostic significance of MRD has been identified in this cohort of patients included in MRD-oriented trials. This gene signature (WOG) together with MRD could help to improve risk-stratification of adult T-ALL patients and would be of interest in the search for new therapies for HR patients Funding: Support from AECC (GC16173697BIGA); ISCIII (PI19/01828 and PI19/01183), co-funded by ERDF/ESF, \"A way to make Europe\"/\"Investing in your future\", CERCA/Generalitat de Catalunya SGR 2017 288 (GRC)/ C Gonz\u00e1lez-Gil was supported by AGAUR grant (2020 FI_B2 00210). Figure 1 View large Download slide Figure 1 View large Download slide  Close modal Disclosures Diaz-Bey\u00e1:  Jazz: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astellas: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Mercadal:  Gilead Sciences, Inc.: Honoraria, Speakers Bureau; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Tormo:  Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Jazz Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Barba:  Amgen, Celgene, Gilead, Incyte, Jazz Pharmaceuticals, MSD, Novartis, Pfizer and Roche, Jazz Phar,aceuticals: Honoraria; Cqrlos III heqlth Institute, aSOCIACION espanola contra el cancer, PERIS: Research Funding. Maciejewski:  Regeneron: Consultancy; Novartis: Consultancy; Bristol Myers Squibb/Celgene: Consultancy; Alexion: Consultancy. Ribera:  ARIAD: Consultancy, Research Funding, Speakers Bureau; AMGEN: Consultancy, Research Funding, Speakers Bureau; Pfizer: Consultancy, Research Funding, Speakers Bureau; TAKEDA: Consultancy, Research Funding, Speakers Bureau; NOVARTIS: Consultancy, Speakers Bureau; SHIRE: Consultancy, Speakers Bureau.",
    "author_names": [
        "Celia Gonz\u00e1lez-Gil",
        "Mireia Morgades",
        "Francisco Fuster-Tormo",
        "Jesus Garc\u00eda-Chica",
        "Pau Montesinos",
        "Anna Torrent",
        "Marina Diaz-Bey\u00e1",
        "Rosa Coll",
        "Jordi Ribera",
        "Ran Zhao",
        "Maria Lourdes Hermosin",
        "Santiago Mercadal",
        "Jos\u00e9 Gonz\u00e1lez-Campos",
        "M Teresa Artola",
        "Ferran Vall-Llovera",
        "Mar Tormo",
        "Cristina Gil",
        "Pere Barba",
        "Andr\u00e9s Novo",
        "Teresa Bernal del Castillo",
        "Maria Queipo De Llano",
        "Pilar Mart\u00ednez",
        "Teresa Gonz\u00e1lez",
        "Antonia Cladera",
        "Alfons Serrano",
        "Rosa Fern\u00e1ndez-Mart\u00edn",
        "Maria C. Ardaiz",
        "Maria Jesus Vidal",
        "\u00c1ngela Baena",
        "Nuria Lopez-Bigas",
        "Anna Bigas",
        "Jaroslaw P. Maciejewski",
        "Alberto Orfao",
        "Josep-Maria Ribera",
        "Eul\u00e0lia Genesc\u00e0"
    ],
    "author_dict_list": [
        {
            "author_name": "Celia Gonz\u00e1lez-Gil",
            "author_affiliations": [
                "Institut d'Investigaci\u00f3 contra la Leucemia Josep Carreras (IJC), Campus ICO (Institut Catal\u00e0 d'Oncologia)-Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona., Badalona, Spain"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Mireia Morgades",
            "author_affiliations": [
                "Hematology Department, ICO Badalona, Germans Trias i Pujol University Hospital. Universitat Aut\u00f2noma de Barcelona. Josep Carreras Leukemia Research Institute, Badalona, Spain"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francisco Fuster-Tormo",
            "author_affiliations": [
                "MDS Research Group, Institut de Recerca Contra la Leuc\u00e8mia Josep Carreras, Institut Catal\u00e0 d'Oncologia-Hospital Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jesus Garc\u00eda-Chica",
            "author_affiliations": [
                "Institut d'Investigaci\u00f3 contra la Leucemia Josep Carreras (IJC), Campus ICO (Institut Catal\u00e0 d'Oncologia)-Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona., Badalona, Spain"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pau Montesinos",
            "author_affiliations": [
                "Hospital Universitario y Polit\u00e9cnico Le Fe, Valencia, Spain"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Anna Torrent",
            "author_affiliations": [
                "Hematology Department, Institut Catal\u00e0 d'Oncologia Badalona, Badalona, Spain"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marina Diaz-Bey\u00e1",
            "author_affiliations": [
                "Hematology Department, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Rosa Coll",
            "author_affiliations": [
                "Hematology Department, ICO - Hospital Doctor Josep Trueta, Girona, Spain"
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jordi Ribera",
            "author_affiliations": [
                "Hematology Department, ICO-Hospital Germans Trias i Pujol. Josep Carreras Research Institute. Universitat Aut\u00f2noma de Barcelona, Badalona, Spain"
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ran Zhao",
            "author_affiliations": [
                "Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH"
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria Lourdes Hermosin",
            "author_affiliations": [
                "Servicio de Hematolog\u00eda Cl\u00ednica, Hospital de Jerez, Jerez de la Frontera, Jerez de la Frontera, Spain"
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Santiago Mercadal",
            "author_affiliations": [
                "ICO-Hospital Duran i Reynals, Hospitalet De Llobregat, Spain"
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jos\u00e9 Gonz\u00e1lez-Campos",
            "author_affiliations": [
                "Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain"
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "M Teresa Artola",
            "author_affiliations": [
                "Servicio de Hematolog\u00eda Cl\u00ednica, Hospital Universitario de Donostia, Donostia, San Sebastian, ESP"
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ferran Vall-Llovera",
            "author_affiliations": [
                "Hematology Department, Hospital Mutua de Terrassa, Terrassa, Spain"
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mar Tormo",
            "author_affiliations": [
                "Hematology Department, Hospital Cl\u00ednico Universitario, Instituto de Investigaci\u00f3n INCLIVA, Valencia, Valencia, Spain"
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Cristina Gil",
            "author_affiliations": [
                "Servicio de Hematolog\u00eda Cl\u00ednica, Hospital General de Alicante, Alicante, Alicante, Spain"
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pere Barba",
            "author_affiliations": [
                "Department of Hematology, Hospital Universitario Vall d'Hebron, Vall d'Hebron Institute of Oncology, Barcelona, Spain"
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Andr\u00e9s Novo",
            "author_affiliations": [
                "Hematology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain"
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Teresa Bernal del Castillo",
            "author_affiliations": [
                "Instituto Universitario Oncol\u00f3gico e Instituto de Investigaci\u00f3n del Principado de Asturias (IUOPA, ISPA), Oviedo, ESP"
            ],
            "author_rank": 20,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria Queipo De Llano",
            "author_affiliations": [
                "Servicio de Hematolog\u00eda Cl\u00ednica, Hospital Virgen de la Victoria, M\u00e1laga, M\u00e1laga, Spain"
            ],
            "author_rank": 21,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pilar Mart\u00ednez",
            "author_affiliations": [
                "Hospital Doce De Octubre, Madrid, ESP"
            ],
            "author_rank": 22,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Teresa Gonz\u00e1lez",
            "author_affiliations": [
                "Servicio de Hematolog\u00eda Cl\u00ednica, Hospital Universitario de Salamanca, Salamanca, Salamanca, Spain"
            ],
            "author_rank": 23,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Antonia Cladera",
            "author_affiliations": [
                "Hematology Department, Hospital Universitario Son Ll\u00e0tzer, Palma de Mallorca, Spain"
            ],
            "author_rank": 24,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alfons Serrano",
            "author_affiliations": [
                "Hospital HM Sanchinarro, Madrid, ESP"
            ],
            "author_rank": 25,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Rosa Fern\u00e1ndez-Mart\u00edn",
            "author_affiliations": [
                "Clinical Hematology, Servicio de Hematolog\u00eda Cl\u00ednica, Hospital Complejo Hospitalario Universitario Insular Materno Infantil de Canarias, Las Palmas de Gran Canaria, Spain"
            ],
            "author_rank": 26,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria C. Ardaiz",
            "author_affiliations": [
                "Servicio de Hematolog\u00eda Cl\u00ednica, Complejo Hospitalario de Navarra, Pamplona, Pamplona, Spain"
            ],
            "author_rank": 27,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria Jesus Vidal",
            "author_affiliations": [
                "Department of Hematology, Hospital Universitario de Leon, Leon, Spain"
            ],
            "author_rank": 28,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "\u00c1ngela Baena",
            "author_affiliations": [
                "Servicio de Hematolog\u00eda Cl\u00ednica, Complejo Hospitalario de Ja\u00e9n, Ja\u00e9n, Ja\u00e9n, Spain"
            ],
            "author_rank": 29,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Nuria Lopez-Bigas",
            "author_affiliations": [
                "Institut de Recerca Biom\u00e8dica (IRB Barcelona), Institut de Ci\u00e8ncies i Tecnologia de Barcelona, Barcelona, Barcelona, Spain"
            ],
            "author_rank": 30,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Anna Bigas",
            "author_affiliations": [
                "IMIM - Hospital Del Mar Research Institute, Barcelona, ESP"
            ],
            "author_rank": 31,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jaroslaw P. Maciejewski",
            "author_affiliations": [
                "Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH"
            ],
            "author_rank": 32,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alberto Orfao",
            "author_affiliations": [
                "Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca; Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain"
            ],
            "author_rank": 33,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Josep-Maria Ribera",
            "author_affiliations": [
                "Clinical Hematology Department, Ico-Hospital Universitari Germans Trias Y Pujol, Badalona, Barcelona, Spain"
            ],
            "author_rank": 34,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Eul\u00e0lia Genesc\u00e0",
            "author_affiliations": [
                "Institut d'Investigaci\u00f3 contra la Leucemia Josep Carreras (IJC), Campus ICO (Institut Catal\u00e0 d'Oncologia)-Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona., Badalona, Spain"
            ],
            "author_rank": 35,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-06-21T18:41:47",
    "is_scraped": "1"
}